Experience

Edmond Differding, Owner and Managing Director of Differding Consulting has an extensive experience in drug discovery

He studied chemistry and received his Ph.D. from the Université catholique de Louvain (Belgium), followed by post-doctoral studies at the Massachusetts Institute of Technology in Cambridge (Massachusetts, USA).

He started his industrial career at the Central Research Laboratories of Ciba-Geigy AG (now Novartis) in Basel, before joining UCB Pharma in Belgium as Head of Chemical Research. Following the acquisitions by UCB of Celltech (UK) and Schwarz Pharma (Germany) he became Vice President Global Chemistry, in charge of three discovery chemistry teams in the therapeutic areas of central nervous system diseases, inflammation and oncology.

He subsequently became UCB’s Vice President Scientific Affairs, based in Mumbai (India) where he was in charge of identifying and initiating drug discovery collaborations with Indian companies. His track record includes several compounds that reached or currently are in clinical development, as well as numerous preclinical candidate nominations.

In 2010, he left UCB and started his own consultancy activities.

Since 2010, he is Board of Administration Member of the “Fonds National de la Recherche (FNR)” in Luxembourg.

He has served as Editorial Board Member of Drug Discovery Today: Technologies (until 2017), and as International Advisory Board Member of ChemMedChem (2006-2013).

In addition he has been President of the Medicinal Chemistry Division of the Société Royale de Chimie (SRC), Belgium (1998-2013), SRC President (2004-05), Council member of the European Federation for Medicinal Chemistry (EFMC) (1998-2013), and EFMC Secretary (2001-2004). He has also been Titular Member of the IUPAC Division VII - Chemistry and Human Health (2014-2017), and Secretary of IUPAC’s Subcommittee on Drug Discovery and Development (2014-2017).


 

LATEST NEWS

02.06.2017 | THE DRUG DISCOVERY AND DEVELOPMENT INDUSTRY IN INDIA - TWO DECADES OF PROPRIETARY SMALL-MOLECULE R&D

A comprehensive survey of proprietary drug discovery and development efforts by Indian companies between 1994 and mid-2016, focusing on preclinical and clinical development compounds by company, therapeutic indication, mode of action, target class, and development status. The analysis includes the evolution of the overall pipeline over two decades, attrition rates, in-house developments and contributions to Western pharmaceutical pipelines through licensing agreements.

AVAILABLE OPEN ACCESS

28.01.2018 | THE STORY OF INDIAN PHARMA AND BIOTECH - BOOKS TO READ

For all those who are interested in the recent history of the pharmaceutical and biotechnology industry in India, and who want to go beyond annual reports and corporate presentations, four recently published biographies are must-reads. Whereas three books are autobiographies, a fourth one is the result of countless interviews of key players (scientists, current and past coworkers, pharma rivals, ministries, etc…), and gives unique insights into the development of biotechnology in India.

READ MORE